

Bronchitis– Pipeline Insight, 2020

<https://marketpublishers.com/r/BC513F0B20DEN.html>

Date: November 2020

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: BC513F0B20DEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Bronchitis– Pipeline Insight, 2020," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Bronchitis Understanding

Bronchitis: Overview

Bronchitis is a condition in which the airways in the lungs, called bronchial tubes, become inflamed and cause coughing, often with mucus. Bronchitis can be acute or chronic.

Symptoms

Signs and symptoms of both acute and chronic bronchitis include:

a persistent cough, which may produce mucus

wheezing

a low fever and chills

a feeling of tightness in the chest

a sore throat

body aches

breathlessness

headaches

a blocked nose and sinuses

Diagnosis

During the first few days of illness, it can be difficult to distinguish the signs and symptoms of bronchitis from those of a common cold.

Chest X-ray. A chest X-ray can help determine if the patient have pneumonia or another condition that may explain your cough.

Sputum tests. Sputum can also be tested for signs of allergies.

Pulmonary function test.

Treatment

Treatment of acute bronchitis is typically divided into two categories: antibiotic therapy and symptom management. Physicians appear to deviate from evidence-based medical practice in the treatment of bronchitis more than in the diagnosis of the condition.

Bronchitis Emerging Drugs Chapters

This segment of the Bronchitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.

It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bronchitis Emerging Drugs

DW 1601: Daewon Pharmaceutical

Daewon Pharmaceutical is developing DW 1601 for the treatment of Bronchitis.

Further product details are provided in the report.....

Bronchitis: Therapeutic Assessment

This segment of the report provides insights about the different Bronchitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Bronchitis

There are approx. 15+ key companies which are developing the therapies for Bronchitis. The companies which have their Bronchitis drug candidates in the most advanced stage, i.e. phase III include, Daewon Pharmaceutical.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Bronchitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bronchitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bronchitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bronchitis drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Bronchitis R&D. The therapies under development are focused on novel approaches to treat/improve Bronchitis.

Bronchitis Report Insights

Bronchitis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Bronchitis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Bronchitis drugs?

How many Bronchitis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bronchitis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bronchitis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Bronchitis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Zambon SpA

Yuhan Corporation

Theravance Biopharma

Genentech, Inc.

GlaxoSmithKline

Novartis

SolAeroMed Inc.

Reata Pharmaceuticals, Inc.

Pulmatrix

Pharmaxis

PharmaKing

NovaBiotics.

Merck Sharp & Dohme Corp.

Johnson & Johnson Pharmaceutical Research & Development

Ionis Pharmaceuticals, Inc.

Incyte Corporation

EmeraMed

Daewon Pharmaceutical Co., Ltd.

Chong Kun Dang Pharmaceutical

Breath Therapeutics Inc.

Boehringer Ingelheim

BioMarck Pharmaceuticals

Beyond Air

AstraZeneca

APT Pharmaceuticals, Inc.

Abgenix

Abbott

Key Products

N-acetylcysteine (NAC)

YHD001

V-306 candidate vaccine

Tiotropium

TD-4208

Pirfenidone

SB-240563 (Mepolizumab)

AD 237

S1226

Bardoxolone methyl

PUR003

TPI 1020

N02RS1

Combination of Broussonetia spp and Lonicera spp

QBW251

Cysteamine

MK-0476

levofloxacin

ION-827359

Itacitinib

GSK573719

Emeramide

DW1601

CKD-497

Liposomal Cyclosporine A

BIBW 2948

BIO-11006

Nitric Oxide

Acridinium bromide

Formoterol/Budesonide

ABX-IL8

Contents

Introduction

Executive Summary

Bronchitis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Bronchitis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Bronchitis companies' collaborations, Licensing, Acquisition -Deal Value Trends

Bronchitis Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

DW 1601: Daewon Pharmaceutical

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Bronchitis Key Companies

Bronchitis Key Products

Bronchitis- Unmet Needs

Bronchitis- Market Drivers and Barriers

Bronchitis- Future Perspectives and Conclusion

Bronchitis Analyst Views

Bronchitis Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Bronchitis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Bronchitis

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Bronchitis– Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/BC513F0B20DEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BC513F0B20DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970